CTAD 2025 | Combining digital and blood-based biomarkers to improve AD screening and clinical trial enrollment

James Galvin, MD, MPH, Miller School of Medicine, Miami, FL, discusses the combination of a digital computerized biomarker, the Cognivue Clarity, with blood-based biomarkers, the Lucent AD Complete biomarker panel, to improve screening, detection, and recruitment for Alzheimer’s disease (AD) clinical trials. Prof. Galvin highlights that the two-stage screening approach can identify individuals with preclinical AD and those who would require further confirmation biomarkers, such as PET scans. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.